New heart failure drug SHR-4658 enters first human safety trial

NCT ID NCT07230145

Not yet recruiting Disease control Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a single injection of SHR-4658 in 48 healthy volunteers and people with slightly high blood pressure. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may lead to larger studies for heart failure treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-4658 injection
What this could lead to: If successful, this could point toward a new treatment option for heart failure by controlling blood pressure.
What could go wrong: This is an early Phase 1 trial with only 48 participants, focused on safety and dosing. It is too small and early to know if SHR-4658 will effectively treat heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELEVATED BLOOD PRESSURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Beijing Anzhen Hospital Capital Medical University

Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.